Kringle Pharma, Inc. (4884.T)
JPY 812.0
(-0.49%)
JPY 812.0
(-0.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 958.01 Million JPY | 31.31% |
| 2022 | 729.58 Million JPY | 26.66% |
| 2021 | 576.03 Million JPY | -9.88% |
| 2020 | 639.21 Million JPY | 71.95% |
| 2019 | 371.74 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 231.44 Million JPY | 4.02% |
| 2024 Q1 | 187.28 Million JPY | -34.52% |
| 2024 Q2 | 222.49 Million JPY | 18.8% |
| 2023 Q4 | 285.99 Million JPY | -11.38% |
| 2023 FY | 958.01 Million JPY | 31.31% |
| 2023 Q3 | 322.73 Million JPY | 84.99% |
| 2023 Q1 | 174 Million JPY | -25.77% |
| 2023 Q2 | 174.45 Million JPY | 0.26% |
| 2022 FY | 729.58 Million JPY | 26.66% |
| 2022 Q4 | 234.4 Million JPY | 0.0% |
| 2021 FY | 576.03 Million JPY | -9.88% |
| 2020 FY | 639.21 Million JPY | 71.95% |
| 2019 FY | 371.74 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 25.416% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -66.087% |
| GNI Group Ltd. | 9.32 Billion JPY | 89.723% |
| Linical Co., Ltd. | 2.7 Billion JPY | 64.586% |
| Trans Genic Inc. | 2.15 Billion JPY | 55.644% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 35.754% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 68.805% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 48.41% |
| AnGes, Inc. | 8.9 Billion JPY | 89.239% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -1.583% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 95.008% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -131.97% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 1.78% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 62.688% |
| CanBas Co., Ltd. | 278 Million JPY | -244.609% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 16.077% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 47.303% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 40.265% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 59.647% |
| PeptiDream Inc. | 9.68 Billion JPY | 90.111% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 51.137% |
| Ribomic Inc. | 1.1 Billion JPY | 13.356% |
| SanBio Company Limited | 4.53 Billion JPY | 78.894% |
| Healios K.K. | 3.48 Billion JPY | 72.526% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 17.036% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 28.21% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 31.739% |
| StemRIM | 2.07 Billion JPY | 53.853% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 51.209% |
| FunPep Company Limited | 313.82 Million JPY | -205.273% |
| Stella Pharma Corporation | 963.98 Million JPY | 0.62% |
| TMS Co., Ltd. | 943.25 Million JPY | -1.565% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 12.105% |
| Cuorips Inc. | 598.11 Million JPY | -60.171% |
| K Pharma,Inc. | 543.94 Million JPY | -76.124% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.992% |
| ReproCELL Incorporated | 1.51 Billion JPY | 36.724% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 19.086% |
| StemCell Institute Inc. | 1.16 Billion JPY | 17.564% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 37.067% |
| CellSeed Inc. | 804.93 Million JPY | -19.018% |